AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal fragment of human growth hormone (hGH 176–191), also known as an anti-obesity research peptide. It carries a tyrosine modification at the N-terminus and contains an internal disulfide bond to improve molecular stability. The core design goal is to separate the lipolytic properties of growth hormone from its anabolic and IGF-1 elevating effects. Unlike full hGH, AOD9604 does not bind to the GH receptor, will not raise IGF-1 level, and does not interfere with glucose and insulin balance.

In preclinical research models, AOD9604 activates β-3 adrenergic receptors on adipocytes, triggers the lipolysis pathway to break down stored triglycerides, and meanwhile inhibits de novo lipogenesis by suppressing fatty acid synthase and acetyl-CoA carboxylase, limiting new fat formation. Apart from lipid metabolism research, relevant studies also explore its potential application in cartilage repair and joint tissue recovery. This peptide is produced under strict synthesis and purification procedures, each batch comes with COA documentation to confirm purity, moisture and residual solvent indexes, suitable for laboratory research on metabolism, fat regulation and tissue repair mechanism. It has a short plasma half-life, so reconstitution method, solvent selection and storage environment will greatly affect solution stability.